Telix has announced that the first patient has been dosed in a Phase 1 study of its investigational targeted radiation therapy, TLX250, combined with Merck’s DNA-dependent protein kinase (DNA-PK) inhibitor candidate, peposertib (M3814). The study is in patients with solid tumours expressing the potential pan-cancer target, carbonic-anhydrase IX (CAIX). The STARSTRUCK trial is an open-label, single-arm, multicentre dose escalation and dose expansion study to evaluate the safety profile, dosing and activity of TLX250 in combination with peposertib. Telix said the clinical hypothesis is that the combination of TLX250 and a DNA-PK inhibitor enhances potency through their synergistic action on cancer cells. Targeted radiation effectively induces DNA damage in targeted cancer cells and the DNA-PK inhibitor may act to prevent the cell from repairing this damage, resulting in higher potency at lower doses.

Source: The Express Tribune July 20, 2023 04:36 UTC